Acessa Health | August 12, 2020
Educational resource supports the safe and effective use of Lap-RFA for the treatment of symptomatic fibroids.
See the full press release on the Business Wire.
AUSTIN, Texas – August 4, 2020 – Acessa Health Inc., a women’s health innovator advancing uterine-sparing solutions for symptomatic fibroids, highlights the American Association of Gynecologic Laparoscopists (AAGL) publication of a Patient Information Sheet for Laparoscopic Radiofrequency Ablation of Fibroids.
AAGL Patient Information Sheets
AAGL announced in July that the organization is providing complimentary Patient Information Sheets available for doctors to download as a benefit of joining AAGL. The information sheets are intended to provide for patients the most up-to-date information on the following gynecological procedures:
- Laparoscopic Radiofrequency Ablation of Fibroids (the Acessa procedure)
- Laparoscopic or Robotic Myomectomy
- Hysteroscopic Myomectomy
- Laparoscopic Supracervical Hysterectomy
- Total Laparoscopic Hysterectomy
- Laparoscopic or Robotic Treatment of Endometriosis
- Diagnostic Hysteroscopic Dilation and Curettage (D&C)
“My colleagues and I agreed it was important to include Laparoscopic Radiofrequency Ablation of Fibroids in the release of Patient Information Sheets. It is vital for women to understand the options available, especially because women are often seeking uterine-sparing alternatives,” said Kelly N. Wright, M.D., Director of the Division of Minimally Invasive Gynecologic Surgery at Cedars Sinai, who led the committee responsible for creating the patient information sheets.
“The recognition and validation of Laparoscopic Radiofrequency Ablation of Fibroids by AAGL via the Patient Information Sheets is a testament to the society’s dedication to elevate the quality and safety of healthcare for women through education,” said Kim Rodriguez, CEO of Acessa Health.
According to the AAGL website, AAGL is the largest medical society focused on gynecologic surgery, with an international membership of over 8,000 physicians and healthcare providers committed to advancing minimally invasive gynecologic surgery (MIGS). AAGL’s Annual Global Congress is the premier scientific program that provides the world’s finest gynecologic surgeons with the latest education and best practices in MIGS.1
About the Acessa procedure
The Acessa procedure is a minimally invasive, outpatient treatment that involves two small abdominal incisions.2 It uses controlled radiofrequency energy, heat, to cause coagulative necrosis of the fibroid tissue. The treated tissue softens and shrinks over time, allowing fibroid symptoms to resolve with no suturing of the uterine tissue.3 Unlike many alternative interventions, the Acessa procedure optimizes imaging of the uterus by simultaneously displaying the laparoscopic camera view and the ultrasound view in real time, so physicians can identify and treat nearly all locations of fibroids, including those outside the uterine cavity and within the uterine walls.3 Women typically experience minimal discomfort after the procedure, quick return to normal activities in four to five days, and long-term satisfaction and relief.2,3
About Acessa Health Inc.
Acessa Health is a women’s health innovator dedicated to advancing minimally invasive, uterine-sparing solutions for women with symptomatic fibroids. The company introduced the use of radiofrequency ablation under laparoscopic ultrasound guidance for the treatment of uterine fibroids. Acessa is continuing to develop technologies that give women more options. Acessa Health’s headquarters are in Austin, Texas. For more information, visit www.acessaprocedure.com
Contact Information: Elaine Horton [email protected]
- Yelena Havryliuk, MD, Robert Setton, MD, John Carlow, EdD, MPH, Barry D. Shaktman, MD, Management of symptomatic fibroids: review and meta-analysis of the literature (2006 -2016), Journal of the Society of Laparoendoscopic Surgeons, Vol. 21 (3) Jul-Sept 2017
- SG Chudnoff, et al. Outpatient Procedure for the Treatment and Relief of Symptomatic Uterine Myomas. Obstetrics and Gynecology, 2013;121(5):1075–82.
There are potential risks associated with the Acessa procedure. It may not be appropriate for all patients and all patients may not benefit. For information about the indications, contraindications, warnings, and precautions, visit: www.acessaprocedure.com. Rx